Table 1.
Patient characteristics.
| Characteristic | Arm D4 (n = 139) | Arm D1 (n = 139) |
|---|---|---|
| Median age | 63 (35–74) | 64 (25–74) |
| Gender, n (%) | ||
| Male | 95 (68.3) | 97 (69.8) |
| Female | 44 (31.7) | 42 (30.2) |
| ECOG PS, n (%) | ||
| 0 | 107 (77.0) | 106 (76.3) |
| 1 | 32 (23.0) | 33 (23.7) |
| Primary tumor, n (%) | ||
| Esophageal | 56 (40.3) | 53 (38.1) |
| Head and neck | 32 (23.0) | 37 (26.6) |
| Lung | 25 (18.0) | 28 (20.1) |
| Gastric | 10 (7.2) | 6 (4.3) |
| Others | 16 (11.5) | 15 (10.8) |
| Dose of CDDP, n (%) | ||
| ≥70 mg/m2 | 111 (79.9) | 113 (81.3) |
| <70 mg/m2 | 28 (20.1) | 26 (18.7) |
| Concurrent radiotherapy, n (%) | ||
| Yes | 51 (36.7) | 49 (35.3) |
| No | 88 (63.3) | 90 (64.7) |
| Drinking habits | ||
| Yes | 56 (40.3) | 60 (43.2) |
| No | 83 (59.7) | 77 (55.4) |
| N/A | 0 | 2 (1.4) |
| Motion sickness | ||
| Yes | 15 (10.8) | 18 (12.9) |
| No | 124 (89.2) | 119 (85.6) |
| N/A | 0 | 2 (1.4) |
| Morning sicknessa | ||
| Yes | 22 (50.0) | 23 (54.8) |
| No | 22 (50.0) | 18 (42.9) |
| N/A | 0 (0.0) | 1 (2.3) |
CDDP cisplatin, N/A not available, ECOG PS eastern cooperative oncology group performance status.
aThe percentage of patients with or without morning sickness was calculated using the number of female patients as the denominator.